Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis

Denis Wakefield, Angela Jennings, Peter McCluskey

Clinical and Experimental Ophthalmology · 2000 · 18 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

PURPOSE: To demonstrate the safety and effectiveness of intravenous methylprednisolone (IVMP) in the treatment of uveitis in association with multiple sclerosis (MS). METHODS: Uveitis is an unusual manifestation of MS that may be severe, chronic and require systemic immunosuppression therapy. High-dose IVMP has previously been shown to be effective in the treatment of inflammatory eye disease and MS. Eight episodes of uveitis in five patients with MS were treated over a 10-year period in an open, uncontrolled trial. Two patients had chronic anterior uveitis, one patient had bilateral panuveitis and two patients had intermediate uveitis. RESULTS: All patients responded to IVMP with evidence of a decrease in intraocular inflammatory activity and improved visual acuity (VA) within 2 weeks of commencing treatment. There were no severe ocular or systemic steroid side effects. CONCLUSIONS: Intravenous methylprednisolone is an effective, well-tolerated form of therapy for uveitis in patients with MS.

References

21